Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
08/2003
08/21/2003WO2002044209A3 Cytonkine receptor zcytor19
08/21/2003WO2002036611A3 Immunomodulatory peptides derived from heat shock proteins and uses thereof
08/21/2003WO2002036573A3 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
08/21/2003WO2002036162A3 Compositions for treatment of ocular neovascularization and neural injury
08/21/2003WO2002020722A9 Methods and compositions for in vitro targeting
08/21/2003US20030158424 Substituted alpha, beta-anellated butyrolactones
08/21/2003US20030158417 Indole type compound derivatives for use as antiinflammation or antiproliferative agents, treating cardiovascular disorders, Alzheimer's disease
08/21/2003US20030158416 Neutralizing paroxetine hydrochloride in organic solvent, salt formation, crystallization or spray drying to form solvent-free
08/21/2003US20030158409 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
08/21/2003US20030158406 Enzyme inhibitor treating autoimmune diseases, Alzheimer's disease, atherosclerosis
08/21/2003US20030158381 Novel insulin/igf/relaxin family polypeptides and dnas thereof
08/21/2003US20030158379 A DNA molecules encoding the proteins, used in the treatment of bone, connective tissue, tendon, ligament, wound healing and defects to tissues, animal growth factors, cell differentiation of embryonic and stem cells
08/21/2003US20030158376 Relaxin-like factor and methods and uses thereof
08/21/2003US20030158254 Linking an agent to a conjugate moiety that has a greater Vmax for a transporter expressed in plasma membranes of epithelial cells lining a human colon than the agent alone; delayed or sustained release
08/21/2003US20030158250 Agents correcting gene expression regulatory error
08/21/2003US20030158248 N-(2-(1-amidinopyrrol-3-yl)ethyl)-5,6-dihydroxy-1-(2-(2-methox y-3-sulfatopropionylamino)-3-chloro-4-methylvaleroyl)indole-2-carboxamide
08/21/2003US20030158246 For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis.
08/21/2003US20030158243 Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity
08/21/2003US20030158239 Reacting a selenourea and an alpha-haloacyl halide in a solvent and in the presence of a catalyst; useful as raw materials for drugs and agricultural chemicals
08/21/2003US20030158238 Treating diseases such as cancer, inflammatory disorders, restenosis,
08/21/2003US20030158235 Pyridine amido derivatives
08/21/2003US20030158229 Also treating bulimia nervosa, irritable bowel syndrome, urinary incontinence, asthma, bradycardia, and bradyarrhythmia
08/21/2003US20030158226 Treating or preventing emphysema, cancer and dermatological disorders
08/21/2003US20030158225 Novel compounds
08/21/2003US20030158224 Vascular endothelial growth factor receptor tyrosine kinases inhibitors; angiogenesis inhibitors, anticarcinogenic agents
08/21/2003US20030158219 N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
08/21/2003US20030158217 Succinate and malonate complexes treatment of abnormal cell growth, such as cancer, and overexpression of erbB2, and inducing cell death
08/21/2003US20030158216 2-acyl indole derivatives and their use as antitumor agents
08/21/2003US20030158211 Methods and compositions for treatment of central nervous system disorders
08/21/2003US20030158209 Amidomethylcarbonyl-substituted piperazine derivatives containing additional amine groups, useful in treating eating, sexual and skin disorders
08/21/2003US20030158208 Dopamine D4 ligands for the treatment of novelty-seeking disorders
08/21/2003US20030158205 N-benzyl-substituted, e.g., (2S)-1-(p-chlorophenoxy)methyl)-carbonyl-2-methyl-4-(p -fluorobenzyl)piperazine; inhibit the activity of the chemokines, MIP-1 alpha and RANTES
08/21/2003US20030158204 Diamino phenothiazine derivatives and composition comprising same
08/21/2003US20030158202 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders
08/21/2003US20030158201 Method for treating septic shock
08/21/2003US20030158200 E.g., 6-(4-(N'-(4-hydroxy-3-methoxy-2-nitrobenzylidene)-hydrazino)phenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one
08/21/2003US20030158197 Certain alkylene diamine-substituted heterocycles
08/21/2003US20030158192 Activating cytokine biosynthesis, viricides treating a viral disease, antitumor agents, immunomodulators
08/21/2003US20030158185 Novel use of phenylheteroakylamine derivatives
08/21/2003US20030158182 Cyanopyrroles
08/21/2003US20030158179 Quinoline derivatives
08/21/2003US20030158176 Quaternary ammonium compounds
08/21/2003US20030158168 Composition for combined use of aromatase inhibitors
08/21/2003US20030158166 Administration of an anticancer (7-alpha-9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl)-estra-1,3,5,-(10) triene-3,17-diol to a breast cancer patient previously treated with an aromatase inhibitor and failed
08/21/2003US20030158163 Conversion of carboxylic acid substituent in a gonane ring, into the methyl ester, or hydrochlorination of a 9-11-epoxy-9-H-cyclopenta(a)phenanthrene compounds
08/21/2003US20030158162 Administering a therapeutically effective amount of an epoxy-steroidal aldosterone receptor antagonist that contains a 9,11-epoxy group to the patient for reducing intraocular pressure
08/21/2003US20030158161 Administering to the human patient or non- human animal an effective amount of a substituted spirostan derivative to treat neurodegenerative disorders
08/21/2003US20030158159 Administering a calcitonin-like agent and a dehydroepiandrosterone-like agent to treat an indivisual for bone density loss
08/21/2003US20030158155 Mmp-12 inhibitors
08/21/2003US20030158152 Protease inhibitors and their pharmaceutical uses
08/21/2003US20030158149 Administering a nucleoside or a nucleoside analog, such as (5'-fluoro-5-methyl-beta-arabinofuranosyl-uridine) or salt or prodrug that suppresses the expression of hepatitis B surface or preS1 antigen in the host 100-fold
08/21/2003US20030158146 Chemical compounds
08/21/2003US20030158121 Novel $G(y)crystalline form of perindopril tert- butylamine salt, preparation method, and pharmaceutical compositions containing same
08/21/2003US20030158120 Combination product comprising melagatran and a factor xa inhibitor
08/21/2003US20030158119 Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least on
08/21/2003US20030158113 Administering to individual a therapeutically effective amount of osteopontin or a functional fragment
08/21/2003US20030158099 Cancer therapy
08/21/2003US20030158094 Combination product of an aryl-substituted propanolamine derivative with at least one other active ingredient and the use of the product
08/21/2003US20030158081 Genetic polymorphisms in the human HMG-CoA reductase gene and their use in diagnosis and treatment of diseases
08/21/2003US20030157718 Expression of heterologous genes from an IRES translational cassette in retroviral vectors
08/21/2003US20030157711 STAT3 activated stem cell
08/21/2003US20030157649 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
08/21/2003US20030157599 Comprises nucleotide sequence coding prostaglandin E receptor (EP3) for diagnosis and treatment of atherosclerotic diseases; restriction fragment length polymorphisms
08/21/2003US20030157552 Providing a screening assay having stearoyl-CoA desaturase biological activity, contacting sceening assay with a test compound and measuring the biological activity
08/21/2003US20030157531 TAOJIKs as modifiers of the beta-catenin pathway and methods of use
08/21/2003US20030157502 Induce apoptosis; antitumor, anticancer agents
08/21/2003US20030157485 Forensic analysis; chromosome marking
08/21/2003US20030157476 Immortalized human keratinocyte cell line
08/21/2003US20030157178 Injectable depot composition
08/21/2003US20030157171 Chitosan-xanthane hydrogel including in its matrix a poorly water soluble drug which upon swelling of hydrogel in aqueous medium becomes at least partially solubilized and releasable therefrom
08/21/2003US20030157130 Modified to include heterologous insertion downstream of its replicase open reading frames; insertion preferably comprises one or more protein-coding regions ideal for virus-like particles packaging
08/21/2003US20030157107 Agents for preventing or ameliorating insulin resistance and/or obesity
08/21/2003US20030157104 Treatment of refractory human tumors with epidermal growth factor receptor antagonists
08/21/2003US20030157098 Methods for inhibiting brain tumor growth
08/21/2003US20030157095 Invasive and metastic ability of breast cancer cells is proportional to level of peripheral type benzodiazepine receptor expressed, correlates with subcellular localization in that it is found in the nucleus of aggressive tumor cells
08/21/2003US20030157094 Prevention, therapy liver disorders, inflammatory bowel diseases, Crohn's disease; antiulcer agents; rheumatic diseases
08/21/2003US20030157084 Methods for preparing purified prostaglandin E synthase
08/21/2003US20030157078 Identification of a pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell
08/21/2003US20030157055 Modified cytokines for use in cancer therapy
08/21/2003US20030157054 Recombinant tumor specific antibody and use thereof
08/21/2003US20030157032 Antihistamines, bronchodilator agents, antiinflammatory agents; mixture of drug and propellant
08/21/2003DE19937304C2 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen Use of CGRP antagonists for the control of menopausal hot flushes
08/21/2003CA2476618A1 Phenalenone derivatives, method for the production thereof and use of the same
08/21/2003CA2476454A1 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
08/21/2003CA2476366A1 Cancer therapy
08/21/2003CA2476292A1 Helical peptidomimetics
08/21/2003CA2476239A1 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
08/21/2003CA2476223A1 Macrolide antibacterial compounds
08/21/2003CA2476162A1 Jnk inhibitor
08/21/2003CA2476113A1 Beta-sheet mimetics and composition and methods relating thereto
08/21/2003CA2476027A1 Alpha-substituted arylalkyl phosphonate derivatives
08/21/2003CA2475783A1 Benzenesulfonamide derivatives as antipsychotic agents
08/21/2003CA2475708A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003CA2475703A1 Aryl ureas with angiogenesis inhibiting activity
08/21/2003CA2475522A1 Method of radio-labelling biomolecules
08/21/2003CA2475439A1 Novel pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
08/21/2003CA2474885A1 Mutated gene coding for a lat protein and the biological applications thereof
08/21/2003CA2474405A1 Medicament for the treatment of choroidal neovascularisation
08/21/2003CA2474195A1 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
08/21/2003CA2474171A1 Biphenil derivatives and their use as antiandrogenic agents
1 ... 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 ... 1564